 Tumors should be considered negative for ER and PrR by immunohistochemistry IHC 1 positive tumor nuclei, as per American Society of Clinical OncologyCollege of American Pathologists ASCOCAP guideline recommendations, Hammond et al 2010 and negative for HER2 by IHC or fluorescent or chromogenic in situ hybridization FISH or CISH. Patients with equivocal HER2 results by IHC should have the negativity status confirmed by FISH. 